CMS official on Alzheimer's drug coverage decision: Don't read between the lines for other accelerated approvals

Almost a week after finalizing its restrictive decision for amyloid-targeted Alzheimer’s drugs, the Centers for Medicare and Medicaid Services (CMS) now appears to be walking back the idea that this decision will have a ripple effect across other accelerated approvals.